DK1441771T3 - Vandige proteinformuleringer med opreholdt frigivelse - Google Patents

Vandige proteinformuleringer med opreholdt frigivelse

Info

Publication number
DK1441771T3
DK1441771T3 DK02780626T DK02780626T DK1441771T3 DK 1441771 T3 DK1441771 T3 DK 1441771T3 DK 02780626 T DK02780626 T DK 02780626T DK 02780626 T DK02780626 T DK 02780626T DK 1441771 T3 DK1441771 T3 DK 1441771T3
Authority
DK
Denmark
Prior art keywords
sustained release
protein formulations
release protein
aqueous sustained
aqueous
Prior art date
Application number
DK02780626T
Other languages
English (en)
Inventor
Basant Sharma
Renzhe Jin
Sunitha Rudolph
Wing K Cheung
Selima Begum
Marian Kelley
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Application granted granted Critical
Publication of DK1441771T3 publication Critical patent/DK1441771T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK02780626T 2001-11-07 2002-10-25 Vandige proteinformuleringer med opreholdt frigivelse DK1441771T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/037,369 US6818613B2 (en) 2001-11-07 2001-11-07 Aqueous sustained-release formulations of proteins
PCT/US2002/036300 WO2003053471A1 (en) 2001-11-07 2002-10-25 Aqueous sustained-release formulations of proteins

Publications (1)

Publication Number Publication Date
DK1441771T3 true DK1441771T3 (da) 2009-01-05

Family

ID=21893975

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02780626T DK1441771T3 (da) 2001-11-07 2002-10-25 Vandige proteinformuleringer med opreholdt frigivelse

Country Status (20)

Country Link
US (3) US6818613B2 (da)
EP (1) EP1441771B1 (da)
JP (1) JP2005514394A (da)
CN (1) CN1612752A (da)
AR (1) AR037260A1 (da)
AT (1) ATE407701T1 (da)
AU (1) AU2002343666B2 (da)
BR (1) BR0213992A (da)
CA (1) CA2465890A1 (da)
CY (1) CY1110271T1 (da)
DE (1) DE60228864D1 (da)
DK (1) DK1441771T3 (da)
ES (1) ES2312633T3 (da)
HK (1) HK1066468A1 (da)
MX (1) MXPA04004367A (da)
MY (1) MY136952A (da)
PT (1) PT1441771E (da)
SI (1) SI1441771T1 (da)
TW (1) TWI332845B (da)
WO (1) WO2003053471A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291436T2 (de) * 2000-05-15 2005-04-15 Hoffmann La Roche Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE602004013557D1 (de) * 2003-02-28 2008-06-19 Ares Trading Sa FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
US20050209148A1 (en) * 2004-02-20 2005-09-22 Arnon Rosenthal Methods of treating obesity or diabetes using NT-4/5
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
KR101058467B1 (ko) 2004-10-27 2011-08-24 유니버시티 오브 덴버 부신피질 자극 호르몬 유사체 및 관련 방법
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
TW200808352A (en) * 2006-02-02 2008-02-16 Rinat Neuroscience Corp Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
CN101679511A (zh) 2007-06-06 2010-03-24 杜门蒂斯有限公司 多肽、抗体可变域和拮抗剂
WO2008151841A2 (en) * 2007-06-15 2008-12-18 University Of Zurich Treatment for alzheimer' s disease
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US9101586B2 (en) 2007-12-28 2015-08-11 Augustine Bader Topical application and formulation of erythropoietin for skin wound healing
US20110009941A1 (en) * 2009-07-08 2011-01-13 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8357179B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8529596B2 (en) 2009-07-08 2013-09-10 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8795345B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8795317B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Embolic obstruction retrieval devices and methods
US8357178B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
ME02506B (me) 2010-11-11 2017-02-20 Abbvie Biotechnology Ltd VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA
WO2012106657A2 (en) 2011-02-04 2012-08-09 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
DK2726090T3 (da) * 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
TW201842929A (zh) * 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
DE2967337D1 (en) * 1978-06-16 1985-02-07 Kyowa Hakko Kogyo Kk Antithrombotic pharmaceutical preparation containing 2,2'-dithiobis benzamide derivatives and new 2,2'-dithiobis benzamide derivatives
WO1983001198A1 (en) 1981-10-08 1983-04-14 Kurt Frimann Berg Method and composition for treating a patient suffering from interferon-susceptible disorder
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
ES8404783A1 (es) * 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
JPS604186A (ja) * 1983-06-21 1985-01-10 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン化合物
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
JP2001515457A (ja) * 1995-06-07 2001-09-18 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 凝集安定化生理活性物質放出用装置
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
IL125552A0 (en) 1996-02-09 1999-03-12 Amgen Inc Composition comprising interleukin-1 inhibitor and controlled release polymer
KR20000029673A (ko) 1996-08-02 2000-05-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 단일의공유결합된ｎ-말단수용성폴리머를갖는폴리펩티드
TR200000175T2 (tr) 1997-07-23 2001-01-22 Roche Diagnostics Gmbh Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
ATE255634T1 (de) 1997-09-01 2003-12-15 Aventis Pharma Gmbh Rekombinantes humanes erythropoietin mit vorteilhaftem glykosylierungsmuster
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
EP1088084B1 (en) 1998-06-15 2006-09-13 GTC Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion protein
WO2000013710A2 (en) 1998-09-04 2000-03-16 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CO5160256A1 (es) 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
ES2308978T3 (es) 1999-04-09 2008-12-16 Ortho-Mcneil Pharmaceutical, Inc. Composicion farmaceutica de eritropoyetina.
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Also Published As

Publication number Publication date
WO2003053471A1 (en) 2003-07-03
AU2002343666B2 (en) 2007-04-05
CY1110271T1 (el) 2015-01-14
PT1441771E (pt) 2008-10-29
BR0213992A (pt) 2004-08-31
TWI332845B (en) 2010-11-11
MY136952A (en) 2008-12-31
TW200303215A (en) 2003-09-01
EP1441771A1 (en) 2004-08-04
EP1441771B1 (en) 2008-09-10
JP2005514394A (ja) 2005-05-19
US20030148938A1 (en) 2003-08-07
CN1612752A (zh) 2005-05-04
CA2465890A1 (en) 2003-07-03
HK1066468A1 (en) 2005-03-24
US20050164927A1 (en) 2005-07-28
US6818613B2 (en) 2004-11-16
AU2002343666A1 (en) 2003-07-09
US20030181361A1 (en) 2003-09-25
US7282480B2 (en) 2007-10-16
AR037260A1 (es) 2004-11-03
DE60228864D1 (de) 2008-10-23
MXPA04004367A (es) 2005-05-16
SI1441771T1 (sl) 2009-02-28
ES2312633T3 (es) 2009-03-01
ATE407701T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
DK1441771T3 (da) Vandige proteinformuleringer med opreholdt frigivelse
NO20033556L (no) Farmasöytiske formuleringer
DK1390066T3 (da) Vaccinesammensætning
NO20034439L (no) Benzamidinderivater
DE60222056D1 (de) Hebestuhl
ATE420159T1 (de) Grippe-impfstoffzusammensetzung
DK1317177T3 (da) Desinficerende formuleringer
NO20031483D0 (no) Vaksine
NO20024270D0 (no) Vedvarende frigivelsesranolazinformuleringer
NO20040125L (no) Enterale formuleringer
NO20024172L (no) Vaksine
DK1427444T3 (da) West-nil-vaccine
ATE316758T1 (de) Pestizide formulierungen
NO20033882L (no) Vaksine
ITTO20020789A1 (it) Formulazione solida
DE60234592D1 (de) Wässrige zusammensetzung
IS6933A (is) Veirueyðandi samsetningar
DZ3495A1 (fr) Formulations agrochimiques
DE60222900D1 (de) Uv-abschirmende peptid-flavonoid konjugate
ATE268116T1 (de) Mesotrion-formulierungen
DE50102084D1 (de) Hufschutz
FR2821754B1 (fr) Descenceur autobloquant
DE50213834D1 (de) Trennmittel
FR2823666B1 (fr) Composition depilatoires hydrosolubles
SE0102824D0 (sv) Preventivmedel